Latest News

Category: News

See all

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

ASX, News,

Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isotope, actinium-225 (225Ac). This provides Telix with both an additional commercial source of 225Ac and access to a platform technology that enables highly efficient, scalable isotope production for...

Read more

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

ASX, News,

Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for...

Read more

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

News,

Telix today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET product, Illuccix®...

Read more

FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

ASX, News,

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma....

Read more

Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Clinical, News,

Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and...

Read more

Telix Files Form 20-F Registration Statement for Nasdaq ADS

ASX, News,

Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of...

Read more

Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M

ASX, News,

Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3...

Read more

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Events, News,

Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...

Read more

Australian TGA Approves Additional Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

News,

Telix today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide...

Read more

Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

News,

Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA[1]-targeted radionuclide...

Read more